MX2019005330A - Esteroides y conjugados de proteinas de los mismos. - Google Patents
Esteroides y conjugados de proteinas de los mismos.Info
- Publication number
- MX2019005330A MX2019005330A MX2019005330A MX2019005330A MX2019005330A MX 2019005330 A MX2019005330 A MX 2019005330A MX 2019005330 A MX2019005330 A MX 2019005330A MX 2019005330 A MX2019005330 A MX 2019005330A MX 2019005330 A MX2019005330 A MX 2019005330A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- conjugates
- steroids
- gcs
- glucocorticoids
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title abstract 2
- 239000003862 glucocorticoid Substances 0.000 abstract 3
- 229940037128 systemic glucocorticoids Drugs 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describen aquí conjugados de esteroide de proteína que son útiles, por ejemplo, para la entrega específica a objetivo de glucocorticoides (GCs) a las células.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662419365P | 2016-11-08 | 2016-11-08 | |
US201762508317P | 2017-05-18 | 2017-05-18 | |
PCT/US2017/060434 WO2018089373A2 (en) | 2016-11-08 | 2017-11-07 | Steroids and protein-conjugates thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019005330A true MX2019005330A (es) | 2019-09-11 |
Family
ID=60409441
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019005330A MX2019005330A (es) | 2016-11-08 | 2017-11-07 | Esteroides y conjugados de proteinas de los mismos. |
MX2021012927A MX2021012927A (es) | 2016-11-08 | 2019-05-07 | Esteroides y conjugados de proteinas de los mismos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021012927A MX2021012927A (es) | 2016-11-08 | 2019-05-07 | Esteroides y conjugados de proteinas de los mismos. |
Country Status (16)
Country | Link |
---|---|
US (4) | US10711032B2 (es) |
EP (1) | EP3538539A2 (es) |
JP (2) | JP7330101B2 (es) |
KR (2) | KR20190074310A (es) |
CN (2) | CN115651056A (es) |
AU (1) | AU2017359043B2 (es) |
BR (1) | BR112019009019A2 (es) |
CA (1) | CA3042428A1 (es) |
CL (1) | CL2019001259A1 (es) |
CO (1) | CO2019005966A2 (es) |
IL (2) | IL307357A (es) |
MX (2) | MX2019005330A (es) |
PH (1) | PH12019501021A1 (es) |
SG (1) | SG10202104259RA (es) |
WO (1) | WO2018089373A2 (es) |
ZA (1) | ZA201902871B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180126000A1 (en) | 2016-06-02 | 2018-05-10 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
WO2018089373A2 (en) | 2016-11-08 | 2018-05-17 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
JP7364471B2 (ja) * | 2017-05-18 | 2023-10-18 | レゲネロン ファーマシューティカルス,インコーポレーテッド | シクロデキストリンタンパク質薬物コンジュゲート |
JP7426931B2 (ja) * | 2017-11-07 | 2024-02-02 | レゲネロン ファーマシューティカルス,インコーポレーテッド | 抗体薬物コンジュゲートのための親水性リンカー |
KR20200095477A (ko) | 2017-12-01 | 2020-08-10 | 애브비 인코포레이티드 | 글루코코르티코이드 수용체 작용제 및 이의 면역접합체 |
KR20200108002A (ko) * | 2018-01-08 | 2020-09-16 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 항체-접합체 |
US11377502B2 (en) | 2018-05-09 | 2022-07-05 | Regeneron Pharmaceuticals, Inc. | Anti-MSR1 antibodies and methods of use thereof |
MA53455B1 (fr) * | 2018-11-20 | 2022-11-30 | Regeneron Pharma | Dérivés de bis-octahydrophénanthrène carboxamide et leurs conjugués protéiques destinés à être utilisés en tant qu'agonistes de lxr |
BR112022001931A2 (pt) | 2019-08-02 | 2022-06-21 | Mersana Therapeutics Inc | Derivados de bis-[n-((5-carbamoil)-1h-benzo[d]imidazol-2-il)-pirazol-5-carboxamida e compostos relacionados como agonistas de sting (estimulador de genes de interferon) para o tratamento de câncer |
US11958910B2 (en) | 2020-02-28 | 2024-04-16 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind HER2, and methods of use thereof |
KR20240038138A (ko) | 2020-07-13 | 2024-03-22 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도 |
KR20230095070A (ko) | 2020-10-22 | 2023-06-28 | 리제너론 파마슈티칼스 인코포레이티드 | 항-fgfr2 항체 및 이의 사용 방법 |
AU2021377185A1 (en) | 2020-11-10 | 2023-06-08 | Regeneron Pharmaceuticals, Inc. | Selenium antibody conjugates |
EP4255447A1 (en) * | 2020-12-04 | 2023-10-11 | Dyne Therapeutics, Inc. | Antibody-oligonucleotide complexes and uses thereof |
WO2022135332A1 (zh) * | 2020-12-21 | 2022-06-30 | 映恩生物制药(苏州)有限公司 | 一种甾体偶联物 |
WO2022166779A1 (zh) * | 2021-02-04 | 2022-08-11 | 上海森辉医药有限公司 | 糖皮质激素受体激动剂的药物偶联物及其在医药上的应用 |
WO2022171101A1 (zh) * | 2021-02-10 | 2022-08-18 | 映恩生物制药(苏州)有限公司 | 一种甾体偶联物 |
TW202304464A (zh) | 2021-03-23 | 2023-02-01 | 美商美國禮來大藥廠 | 新穎糖皮質素受體激動劑 |
TW202304462A (zh) | 2021-03-23 | 2023-02-01 | 美商美國禮來大藥廠 | 糖皮質素受體激動劑 |
AR125079A1 (es) | 2021-03-23 | 2023-06-07 | Lilly Co Eli | Agonistas de receptores de glucocorticoides sustituidos con carboxi |
CN113264983A (zh) * | 2021-05-20 | 2021-08-17 | 联宁(苏州)生物制药有限公司 | 一种用于抗体偶联药物的连接子lnd1088的合成方法 |
EP4393937A1 (en) * | 2021-08-26 | 2024-07-03 | Duality Biologics (Suzhou) Co., Ltd. | Steroid compound and conjugate thereof |
CN114394933B (zh) * | 2022-01-07 | 2023-08-22 | 厦门沃克沃德医药科技有限公司 | 11,12-二氢-γ-氧代-二苯并[f]偶氮-5-(6h)-丁酸的合成方法 |
AU2023207960A1 (en) | 2022-01-12 | 2024-07-11 | Regeneron Pharmaceuticals, Inc. | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
WO2023173121A1 (en) | 2022-03-11 | 2023-09-14 | Firefly Bio, Inc. | Phenyl maleimide linker agents |
WO2023220549A1 (en) | 2022-05-13 | 2023-11-16 | Eli Lilly And Company | Human tumor necrosis factor alpha antibody glucocorticoid conjugates |
WO2023222019A1 (zh) * | 2022-05-18 | 2023-11-23 | 成都百利多特生物药业有限责任公司 | 配体药物偶联物及其应用 |
US20240100176A1 (en) | 2022-06-02 | 2024-03-28 | Eli Lilly And Company | Human interleukin-4 receptor alpha antibody glucocorticoid conjugates |
US20240173425A1 (en) | 2022-06-22 | 2024-05-30 | Eli Lilly And Company | Human cd33 antibodies and glucocorticoid conjugates |
US20240218011A1 (en) | 2022-07-21 | 2024-07-04 | Firefly Bio, Inc. | Glucocorticoid receptor agonists and conjugates thereof |
WO2024064779A1 (en) | 2022-09-22 | 2024-03-28 | Eli Lilly And Company | Glucocorticoid receptor agonists |
US20240269308A1 (en) | 2022-12-21 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof |
WO2024140838A1 (zh) * | 2022-12-28 | 2024-07-04 | 映恩生物制药(苏州)有限公司 | 抗bdca2抗体-药物偶联物及其用途 |
WO2024153162A1 (en) * | 2023-01-18 | 2024-07-25 | Shanghai Micurx Pharmaceutical Co., Ltd. | Peptide-drug conjugates for targeted therapy of renal diseases |
Family Cites Families (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2737518A (en) * | 1955-01-19 | 1956-03-06 | Schering Corp | 1-hydroxycortisone, 1-hydroxyhydrocortisone and esters thereof |
US2968655A (en) * | 1956-11-23 | 1961-01-17 | Upjohn Co | 11-oxygenated-6-methyl progesterone and intermediates therefor |
US2920999A (en) | 1957-06-07 | 1960-01-12 | Pfizer & Co C | 21-nitrogen derivatives of corticosteroids |
GB889766A (en) | 1958-03-04 | 1962-02-21 | Olin Mathieson | Improvements in steroids and the synthesis thereof |
DE1165595B (de) | 1958-03-04 | 1964-03-19 | Olin Mathieson | Verfahren zur Herstellung von Triamcinolonacetonid-21-hemisuccinat und dessen Salzen |
US3197469A (en) | 1958-08-06 | 1965-07-27 | Pharmaceutical Res Products In | 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor |
US3007923A (en) * | 1959-01-22 | 1961-11-07 | Lab Francais Chimiotherapie | Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids |
GB898295A (en) | 1959-03-18 | 1962-06-06 | Upjohn Co | Improvements in or relating to steroids and the manufacture thereof |
US3033874A (en) | 1960-05-11 | 1962-05-08 | Pfizer & Co C | 17beta-propenoyl steroids and process for preparing same |
US3033873A (en) | 1960-05-11 | 1962-05-08 | Pfizer & Co C | 21-aminomethyl-pregnenes |
US3020275A (en) | 1960-06-07 | 1962-02-06 | American Cyanamid Co | 21-nitrogen substituted steroids of the pregnane series and methods of preparing the same |
DE1169444B (de) * | 1961-02-22 | 1964-05-06 | Schering Ag | Verfahren zur Herstellung von ?-16ª-Methylsteroiden |
US3047468A (en) * | 1961-06-06 | 1962-07-31 | American Cyanamid Co | Method of preparing delta1, 4-3-keto steroids of the pregnane series |
US3383394A (en) * | 1965-08-30 | 1968-05-14 | Schering Corp | Novel 17-acylating process and products thereof |
US3798216A (en) | 1969-03-07 | 1974-03-19 | Fabrication Des Antibiotique S | 9-fluoro-11beta,21-dihydroxy-16alpha,17-(2-propenylidenedioxy)-pregna-1,4-diene-3,20-dione and derivatives thereof |
DE2047105C3 (de) | 1970-09-18 | 1979-02-15 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | 17-Chlorsteroide und Verfahren zu ihrer Herstellung |
IT1057859B (it) | 1972-04-28 | 1982-03-30 | Sigma Tao Ind Farmaceutiche Sp | Perivato del triamoinolone |
SE378110B (es) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
SE378109B (es) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
US4076737A (en) | 1975-02-20 | 1978-02-28 | Ciba-Geigy Corporation | Aldehydes of the pregnane series and derivatives thereof |
IL73337A (en) | 1984-10-28 | 1988-09-30 | Yissum Res Dev Co | Antitumor steroid-platinum complexes and method for the preparation thereof |
ES8605537A1 (es) | 1985-07-03 | 1986-02-01 | Elmu Sa | Procedimiento de obtencion de cetales ciclicos de corticoi- des y sus 21-c esteres |
SE8604059D0 (sv) | 1986-09-25 | 1986-09-25 | Astra Pharma Prod | A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5116829A (en) | 1990-04-23 | 1992-05-26 | Kao Corporation | Steroid compounds |
US5183815A (en) | 1991-01-22 | 1993-02-02 | Merck & Co., Inc. | Bone acting agents |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
WO1994015947A1 (en) | 1993-01-08 | 1994-07-21 | Astra Aktiebolag | Novel colon- or ileum-specific steroid derivatives |
DE4311987A1 (de) | 1993-04-07 | 1994-10-13 | Schering Ag | Neue Glucocorticoide |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5824669A (en) | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
US5837698A (en) | 1996-05-02 | 1998-11-17 | G. D. Searle & Co. | Steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs |
WO2000049993A2 (en) | 1999-02-24 | 2000-08-31 | Nitromed, Inc. | Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
SE0101220D0 (sv) | 2001-04-04 | 2001-04-04 | Astrazeneca Ab | New use |
US6908934B2 (en) | 2001-06-11 | 2005-06-21 | Merck & Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
ITMI20020148A1 (it) | 2002-01-29 | 2003-07-29 | Nicox Sa | Nuovi corticosteroidi |
US20050009798A1 (en) | 2002-02-20 | 2005-01-13 | Sepracor Inc. | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists |
US7190468B2 (en) | 2002-07-17 | 2007-03-13 | Hewlett-Packard Development Company, L.P. | Background document rendering system and method |
US7659241B2 (en) | 2002-07-31 | 2010-02-09 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
AU2003265576A1 (en) * | 2002-08-23 | 2004-03-11 | The Mclean Hospital Corporation | Corticosteroid conjugates and uses thereof |
CN102516417B (zh) | 2002-09-06 | 2014-12-10 | 天蓝制药公司 | 用于传递治疗剂的以环糊精为基础的聚合物 |
CN1414008A (zh) | 2002-10-17 | 2003-04-30 | 南开大学 | 含氮甾体化合物及其制备方法 |
US7015349B2 (en) | 2003-03-26 | 2006-03-21 | The Gillette Company | Reduction of hair growth |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
WO2005063777A1 (en) * | 2003-12-23 | 2005-07-14 | Corus Pharma | Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation |
US20050192257A1 (en) | 2004-02-26 | 2005-09-01 | Peyman Gholam A. | Predictors for patients at risk for glaucoma from steroid therapy |
AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
EP2286844A3 (en) | 2004-06-01 | 2012-08-22 | Genentech, Inc. | Antibody-drug conjugates and methods |
EP1602931A1 (en) | 2004-06-03 | 2005-12-07 | Universiteit Leiden | SR-A antagonists |
US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
ATE411053T1 (de) | 2004-08-09 | 2008-10-15 | Deutsches Krebsforsch | Albuminkonjugate, die eine glucuron-verknüpfung enthalten |
TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
AU2005316844A1 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
WO2006135371A1 (en) | 2005-06-09 | 2006-12-21 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
US20100209508A1 (en) * | 2005-06-14 | 2010-08-19 | Corus Pharma, Inc. | Substituted Phenylphosphates as Mutual Prodrugs of Steroids and ß-Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction |
US20070135398A1 (en) | 2005-11-02 | 2007-06-14 | Pierluigi Rossetto | Process for the preparation of ciclesonide |
BRPI0620434A2 (pt) | 2005-12-22 | 2011-11-16 | Baxter Int | teste aperfeiçoado de ativação de monócitos capaz de detectar melhor contaminantes pirogênicos não-endotóxicos em produtos médicos |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
US20100041633A1 (en) | 2007-02-05 | 2010-02-18 | Nicox S.A. | Nitric oxide releasing steroids |
WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
JP2010528285A (ja) | 2007-05-23 | 2010-08-19 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 免疫組織化学およびinsituハイブリダーゼーションのためのポリマー担体 |
US9138484B2 (en) | 2007-06-25 | 2015-09-22 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
CA2692021A1 (en) | 2007-06-28 | 2008-12-31 | Capsutech Ltd | Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers |
CN101397328A (zh) | 2007-09-27 | 2009-04-01 | 天津药业研究院有限公司 | 一氧化氮供体型糖皮质激素 |
DK2214646T3 (da) | 2007-10-05 | 2021-10-04 | Univ Wayne State | Dendrimers for sustained release of compounds |
JP2011507878A (ja) * | 2007-12-21 | 2011-03-10 | シェーリング コーポレイション | C20−c21置換グルココルチコイド受容体アゴニスト |
AR070040A1 (es) | 2007-12-21 | 2010-03-10 | Schering Corp | Tioeteres c-21 como agonistas del receptor de glucocorticoides |
SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
EP2294077A1 (en) | 2008-06-10 | 2011-03-16 | Gilead Sciences, Inc. | Corticosteroid linked beta-agonist compounds for use in therapy |
ES2536882T3 (es) | 2008-07-21 | 2015-05-29 | Polytherics Limited | Nuevos reactivos y procedimiento de conjugación de moléculas biológicas |
AU2009273251B2 (en) | 2008-07-22 | 2014-12-18 | Ablynx Nv | Amino acid sequences directed against multitarget scavenger receptors and polypeptides |
CN102348714B (zh) | 2009-03-09 | 2015-01-07 | 三笠制药株式会社 | 甾族化合物 |
WO2010126953A1 (en) | 2009-04-29 | 2010-11-04 | Gilead Sciences, Inc. | Corticosteroid linked beta-agonist compounds for use in therapy |
WO2010132743A1 (en) | 2009-05-15 | 2010-11-18 | Gilead Sciences, Inc. | Corticosteroid beta-agonist compounds for use in therapy |
CA2770626A1 (en) | 2009-08-10 | 2011-02-17 | Mark Smith | Functionalisation of solid substrates |
WO2011020107A2 (en) | 2009-08-14 | 2011-02-17 | Georgetown University | Compositions and methods for detection and treatment of breast cancer |
GB0917044D0 (en) | 2009-09-29 | 2009-11-18 | Cytoguide As | Agents, uses and methods |
GB0917054D0 (en) * | 2009-09-29 | 2009-11-11 | Cytoguide As | Agents, uses and methods |
WO2011081937A1 (en) | 2009-12-15 | 2011-07-07 | Gilead Sciences, Inc. | Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy |
WO2011090940A1 (en) | 2010-01-19 | 2011-07-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
US9375473B2 (en) | 2010-02-19 | 2016-06-28 | Cornell Research Foundation, Inc. | Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases |
JP5972864B2 (ja) | 2010-04-15 | 2016-08-17 | メディミューン リミテッド | ピロロベンゾジアゼピン及びそれらのコンジュゲート |
WO2012005982A2 (en) | 2010-07-06 | 2012-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Reporter for rna polymerase ii termination |
KR102434557B1 (ko) | 2010-08-02 | 2022-08-23 | 리제너론 파아마슈티컬스, 인크. | Vl 도메인을 포함하는 결합 단백질을 생성하는 마우스 |
MX339739B (es) | 2010-09-01 | 2016-06-07 | Bayer Ip Gmbh | N-(tetrazol-5-il)-y n-(triazol-5-il)arilcarboxamidas y su uso como herbicidas. |
EA201390575A1 (ru) | 2010-10-29 | 2014-01-30 | Иммьюноджен, Инк. | Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты |
WO2012145632A1 (en) | 2011-04-21 | 2012-10-26 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
MX371526B (es) | 2011-05-27 | 2020-01-31 | Ambrx Inc | Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales. |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
EP3388435B1 (en) | 2011-10-14 | 2023-05-03 | Seagen Inc. | Pyrrolobenzodiazepines and targeted conjugates |
EA028457B1 (ru) | 2011-10-14 | 2017-11-30 | Медимьюн Лимитед | Пирролобензодиазепины |
EA036202B1 (ru) | 2011-10-14 | 2020-10-14 | Сиэтл Дженетикс, Инк. | Пирролбензодиазепины и конъюгаты направленного действия |
JP6166728B2 (ja) | 2011-10-14 | 2017-07-19 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体 |
WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
JP2015500287A (ja) | 2011-12-05 | 2015-01-05 | アイジェニカ・バイオセラピューティクス・インコーポレイテッドIgenica Biotherapeutics,Inc. | 抗体−薬物のコンジュゲート、ならびに関連する化合物、組成物および方法 |
GB201122325D0 (en) | 2011-12-23 | 2012-02-01 | Cytoguide As | Novel formulations |
WO2013188740A1 (en) | 2012-06-14 | 2013-12-19 | Ambrx, Inc. | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
SG11201501920PA (en) | 2012-10-11 | 2015-04-29 | Ascendis Pharma As | Diagnosis, prevention and treatment of diseases of the joint |
SG11201502896XA (en) | 2012-10-16 | 2015-05-28 | Endocyte Inc | Drug delivery conjugates containing unnatural amino acids and methods for using |
LT3912642T (lt) | 2012-10-23 | 2023-07-25 | Synaffix B.V. | Modifikuotas antikūnas, antikūno konjugatas ir jų gamybos būdas |
US9376420B2 (en) | 2012-10-25 | 2016-06-28 | Yuhan Corporation | 4,5-dihydro-1H-pyrazole derivative or salts thereof, and pharmaceutical composition comprising same |
US9725515B2 (en) | 2012-12-24 | 2017-08-08 | Abbvie Inc. | Prolactin receptor binding proteins and uses thereof |
EA201591710A1 (ru) | 2013-03-13 | 2016-03-31 | Сиэтл Дженетикс, Инк. | Композиции, содержащие циклодекстрин и конъюгат антитело-лекарственное средство |
EP2988786A4 (en) * | 2013-04-22 | 2016-12-21 | Avelas Biosciences Inc | COMPOSITIONS AND METHODS OF USE FOR SELECTIVE DRUG DELIVERY |
US11229711B2 (en) | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
CN105517577A (zh) | 2013-06-21 | 2016-04-20 | 先天制药公司 | 多肽的酶促偶联 |
WO2015005459A1 (ja) | 2013-07-10 | 2015-01-15 | 生化学工業株式会社 | 呼吸器投与用の医薬組成物 |
TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
CN105764503A (zh) | 2013-10-15 | 2016-07-13 | 西雅图基因公司 | 用于改善配体-药物偶联物药代动力学的peg化的药物-接头 |
GB201320091D0 (en) | 2013-11-14 | 2014-01-01 | Univ Manchester | Selective glucocorticoid receptor ligands |
CN103694375B (zh) | 2013-12-13 | 2016-10-05 | 北京大学 | 一种三萜-环糊精共价化合物及其制备方法和用途 |
WO2015110609A1 (en) | 2014-01-24 | 2015-07-30 | Centre National De La Recherche Scientifique | Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating e. coli induced inflammatory bowel diseases such as crohn's disease |
US10550190B2 (en) | 2014-04-04 | 2020-02-04 | Merck Sharp & Dohme Corp. | Phosphate based linkers for intracellular delivery of drug conjugates |
CN111228511B (zh) | 2014-04-10 | 2024-06-18 | 第一三共株式会社 | 抗her3抗体-药物偶联物 |
EP3166638A1 (en) | 2014-06-13 | 2017-05-17 | Glykos Finland Oy | Payload-polymer-protein conjugates |
EP3226911A1 (en) | 2014-12-03 | 2017-10-11 | F.Hoffmann-La Roche Ag | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
BR112017011478A2 (pt) | 2014-12-03 | 2018-02-27 | Genentech, Inc. | composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante |
WO2016094509A1 (en) | 2014-12-09 | 2016-06-16 | Abbvie Inc. | Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same |
MX2017007637A (es) | 2014-12-09 | 2017-09-05 | Abbvie Inc | Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen. |
US10233210B2 (en) | 2015-01-30 | 2019-03-19 | Coral Drugs Pvt. Ltd. | Process for preparation of glucocorticoid steroids |
CA2976064A1 (en) | 2015-02-06 | 2016-08-11 | Sorrento Therapeutics, Inc. | Antibody drug conjugates |
WO2017006279A1 (en) | 2015-07-08 | 2017-01-12 | Aten Porus Lifesciences | Cyclodextrin-polymer complexes and compostions and methods of making and using the same |
EP3346997A4 (en) | 2015-09-10 | 2019-05-15 | Shasqi, Inc. | BIOORTHOGONAL COMPOSITIONS |
US11510993B2 (en) | 2015-10-06 | 2022-11-29 | Merck Sharp & Dohme Llc | Antibody drug conjugate for anti-inflammatory applications |
WO2017132103A2 (en) | 2016-01-29 | 2017-08-03 | Merck Sharp & Dohme Corp. | Phosphonate linkers and their use to facilitate cellular retention of compounds |
EP3419670A2 (en) | 2016-02-26 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
CN109843919A (zh) | 2016-03-25 | 2019-06-04 | 西雅图基因公司 | 用于制备聚乙二醇化的药物-接头及其中间体的方法 |
GB201608936D0 (en) | 2016-05-20 | 2016-07-06 | Polytherics Ltd | Novel conjugates and novel conjugating reagents |
US20180126000A1 (en) | 2016-06-02 | 2018-05-10 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
US20200147235A1 (en) | 2016-06-08 | 2020-05-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
CA3037732A1 (en) | 2016-09-23 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
WO2018089373A2 (en) | 2016-11-08 | 2018-05-17 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
RU2765098C2 (ru) | 2017-02-28 | 2022-01-25 | Иммуноджен, Инк. | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты |
JP7364471B2 (ja) | 2017-05-18 | 2023-10-18 | レゲネロン ファーマシューティカルス,インコーポレーテッド | シクロデキストリンタンパク質薬物コンジュゲート |
IL270595B2 (en) | 2017-05-18 | 2023-09-01 | Regeneron Pharma | Bi-octahydrophenanthrene carboxamides and their protein conjugates |
CN118652192A (zh) | 2017-05-24 | 2024-09-17 | 德克萨斯州大学系统董事会 | 用于抗体药物缀合物的接头 |
CN109106951A (zh) | 2017-08-18 | 2019-01-01 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
WO2019034177A1 (zh) | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 具有两种不同药物的抗体药物偶联物 |
JP7426931B2 (ja) | 2017-11-07 | 2024-02-02 | レゲネロン ファーマシューティカルス,インコーポレーテッド | 抗体薬物コンジュゲートのための親水性リンカー |
KR20200108002A (ko) | 2018-01-08 | 2020-09-16 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 항체-접합체 |
AR114473A1 (es) | 2018-04-06 | 2020-09-09 | Seattle Genetics Inc | Conjugados péptido-camptotecina |
US11377502B2 (en) | 2018-05-09 | 2022-07-05 | Regeneron Pharmaceuticals, Inc. | Anti-MSR1 antibodies and methods of use thereof |
CA3123607A1 (en) | 2018-12-21 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Rifamycin analogs and antibody-drug conjugates thereof |
EP3908323A2 (en) | 2019-01-08 | 2021-11-17 | Regeneron Pharmaceuticals, Inc. | Traceless linkers and protein-conjugates thereof |
-
2017
- 2017-11-07 WO PCT/US2017/060434 patent/WO2018089373A2/en active Application Filing
- 2017-11-07 CN CN202211283749.2A patent/CN115651056A/zh active Pending
- 2017-11-07 SG SG10202104259RA patent/SG10202104259RA/en unknown
- 2017-11-07 BR BR112019009019A patent/BR112019009019A2/pt unknown
- 2017-11-07 US US15/806,197 patent/US10711032B2/en active Active
- 2017-11-07 KR KR1020197015823A patent/KR20190074310A/ko not_active Application Discontinuation
- 2017-11-07 CN CN201780082517.1A patent/CN110291097A/zh active Pending
- 2017-11-07 JP JP2019523684A patent/JP7330101B2/ja active Active
- 2017-11-07 KR KR1020247004647A patent/KR20240025695A/ko active Application Filing
- 2017-11-07 EP EP17801239.9A patent/EP3538539A2/en active Pending
- 2017-11-07 MX MX2019005330A patent/MX2019005330A/es unknown
- 2017-11-07 IL IL307357A patent/IL307357A/en unknown
- 2017-11-07 IL IL266353A patent/IL266353B2/en unknown
- 2017-11-07 AU AU2017359043A patent/AU2017359043B2/en active Active
- 2017-11-07 CA CA3042428A patent/CA3042428A1/en active Pending
-
2018
- 2018-11-06 US US16/761,493 patent/US20210332080A1/en active Pending
-
2019
- 2019-05-07 ZA ZA2019/02871A patent/ZA201902871B/en unknown
- 2019-05-07 CL CL2019001259A patent/CL2019001259A1/es unknown
- 2019-05-07 MX MX2021012927A patent/MX2021012927A/es unknown
- 2019-05-08 PH PH12019501021A patent/PH12019501021A1/en unknown
- 2019-06-07 CO CONC2019/0005966A patent/CO2019005966A2/es unknown
-
2020
- 2020-04-24 US US16/858,458 patent/US11760775B2/en active Active
-
2023
- 2023-07-28 US US18/361,275 patent/US20240101594A1/en active Pending
- 2023-08-08 JP JP2023129158A patent/JP2023153988A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL266353B1 (en) | 2023-11-01 |
KR20190074310A (ko) | 2019-06-27 |
US20210040144A1 (en) | 2021-02-11 |
AU2017359043A1 (en) | 2019-05-23 |
IL266353B2 (en) | 2024-03-01 |
SG10202104259RA (en) | 2021-06-29 |
US10711032B2 (en) | 2020-07-14 |
CA3042428A1 (en) | 2018-05-17 |
JP2019536765A (ja) | 2019-12-19 |
WO2018089373A2 (en) | 2018-05-17 |
JP2023153988A (ja) | 2023-10-18 |
CL2019001259A1 (es) | 2019-07-19 |
JP7330101B2 (ja) | 2023-08-21 |
PH12019501021A1 (en) | 2019-06-24 |
US11760775B2 (en) | 2023-09-19 |
MX2021012927A (es) | 2022-01-31 |
US20210332080A1 (en) | 2021-10-28 |
AU2017359043B2 (en) | 2022-06-16 |
EP3538539A2 (en) | 2019-09-18 |
BR112019009019A2 (pt) | 2019-07-09 |
WO2018089373A3 (en) | 2018-06-21 |
CO2019005966A2 (es) | 2019-07-10 |
CN115651056A (zh) | 2023-01-31 |
US20180155389A1 (en) | 2018-06-07 |
CN110291097A (zh) | 2019-09-27 |
KR20240025695A (ko) | 2024-02-27 |
US20240101594A1 (en) | 2024-03-28 |
IL266353A (en) | 2019-06-30 |
ZA201902871B (en) | 2023-12-20 |
WO2018089373A9 (en) | 2018-07-12 |
IL307357A (en) | 2023-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501021A1 (en) | Steroids and protein-conjugates thereof | |
PH12020551044A1 (en) | Steroids and antibody-conjugates thereof | |
PH12017502390A1 (en) | Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof | |
MX2018011706A (es) | Composicion farmaceutica de hormona esteroide. | |
BR112018014760A2 (pt) | anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos | |
MX2018015272A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
MY186708A (en) | Constructs targeting afp peptide/mhc complexes and uses thereof | |
EP3426257A4 (en) | NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF | |
MX2018003689A (es) | Proteinas de union a pd-1 y metodos para usarlas. | |
AU2018253589A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
MA40459A (fr) | Anticorps anti-age pour le traitement de l'inflammation et de troubles auto-immuns | |
MX2018015274A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
ZA201807920B (en) | Anti¿gitr antibodies and uses thereof | |
WO2020051333A8 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
WO2018119425A3 (en) | Anti-lilrb3 antibodies and methods of use thereof | |
WO2018183182A8 (en) | Methods and compositions for reduction of immunogenicity | |
EP3462875A4 (en) | COMPOSITIONS AND METHODS WITH THE ANDERSTENONE, TESTOSTERONE, PROGESTERONE AND ESTROGEN PHEROMONIC COMPOUNDS | |
PH12018500159A1 (en) | Constructs targeting psa peptide/mhc complexes and uses thereof | |
MX2018010491A (es) | Proceso para la preparacion de un conjugado anticuerpo-rifamicina. | |
CR20210088A (es) | Composiciones de anticuerpos fcrn y métodos de uso de estos | |
WO2018175740A8 (en) | Anti-tmeff1 antibodies and antibody drug conjugates | |
CY1125282T1 (el) | Υδροξυλιωση στη θεση 21 των στεροειδων | |
MX2019005933A (es) | Polipeptidos biespecificos para gitr y ctla-4. | |
EP3886921A4 (en) | ACTINIUM 225 AND ACTINIUM 227 CONJUGATED ANTIBODIES, COMPOSITIONS AND METHODS RELATED |